Sinco Pharmaceuticals FY2025 net profit drops 16.9% to RMB34.9 million; revenue falls 26.1% to RMB2.1 billion

Reuters03-26
Sinco Pharmaceuticals FY2025 net profit drops 16.9% to RMB34.9 million; revenue falls 26.1% to RMB2.1 billion
  • Sinco published an annual results announcement reporting revenue of RMB2.08 billion, down 26.1%, mainly due to lower sales volume of human albumin solution.
  • Gross profit fell 25.9% to RMB222.09 million, while gross margin was 10.7%, up 0.1 percentage point.
  • Profit attributable to owners declined 16.9% to RMB34.85 million, and basic and diluted EPS was RMB0.017.
  • Finance costs rose to RMB33.94 million, driven mainly by a RMB12.99 million guarantee fee paid to chairman Huang and higher interest and letter-of-credit charges.
  • Management said it expects industry competition to remain intense amid ongoing centralized procurement and pricing pressure, while it continues to expand hospital coverage for its core biologics products and advance medical aesthetics R&D, including a December 2025 launch-registration submission for its polycaprolactone filler product.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinco Pharmaceuticals Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12070226), on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment